#United States #Miami Beach #Azitra #ATR-12 #Precision Dermatology

Azitra, Inc. to Present at BIO Investment & Growth Summit

Azitra, Inc., a clinical stage biopharmaceutical company publicly traded on the NYSE under the ticker AZTR, will participate in the forthcoming BIO Investment & Growth Summit. The event is set to take place at the renowned Eden Roc Miami Beach Hotel in Florida from March 2nd to March 3rd, 2026. This gathering is pivotal for companies in the biotech sector to showcase their latest advancements and explore potential investments.

Event Highlights

On March 2, 2026, at 2:15 PM ET, Azitra's Chief Operating Officer, Travis Whitfill, will take center stage to present the company’s recent progress and developments within its pipeline. Attendees can look forward to insightful updates on several of Azitra's key programs:

• - ATR-12: Currently undergoing a Phase 1b clinical trial, this innovative therapy is designed to treat Netherton syndrome, a rare genetic skin condition with no approved treatment options available. This condition poses life-threatening challenges and necessitates effective therapeutic strategies.
• - ATR-04: In its Phase 1/2 trial, this program aims to address moderate to severe dermal toxicity associated with EGFR inhibitors in adult patients. The FDA has already granted this candidate Fast Track designation, highlighting the urgency and need for such a treatment, which affects around 150,000 people in the U.S.
• - ATR-01: Targeting ichthyosis vulgaris, this program is in the stages of IND-enabling studies, further solidifying Azitra's commitment to addressing various dermatological conditions.

Meeting Opportunities

The summit will not only host the presentation but also facilitate one-on-one meetings between Azitra’s management team and registered investors or potential partners. This is an excellent opportunity for stakeholders to engage directly with the leadership and glean insights into the company’s strategic vision for clinical development, recent corporate milestones, and future prospects.

About Azitra, Inc.

Founded with a focus on precision dermatology, Azitra, Inc. is at the forefront of developing ground-breaking therapies for various skin conditions. Their lead product, ATR-12, highlights the company's innovative approach, employing an engineered strain of Staphylococcus epidermidis to target a chronic skin disorder. Additionally, Azitra leverages a proprietary platform that includes around 1,500 bacterial strains, enhanced through artificial intelligence and machine learning to identify potential drug candidates swiftly.

The commitment to transforming treatment paradigms in dermatology underpins every aspect of Azitra’s mission, making the upcoming summit a significant marker of their ongoing journey within this specialized field.

For more details about Azitra and its initiatives, please visit Azitra’s official website.

Forward-Looking Statements

This announcement contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Such statements, which may involve risks and uncertainties, include details about the expected timing of clinical trials and potential effects of external regulatory conditions. Investors are urged to refer to the company's filings for insights into these potential risks. Azitra disclaims any obligation to update forward-looking statements except as required by law.

Overall, Azitra, Inc. continues to position itself as a leader in the biopharmaceutical arena, dedicated to developing innovative solutions for unmet medical needs in dermatology.